“We believe the future of HIV treatment is long-acting injectables, and Livimmune is actively pursuing a long-acting version of leronlimab. This could be potentially used in combination with standard-of-care therapies to treat HIV patients and could prove to be of great use in HIV pre-exposure prophylaxis (“PrEP”). In the absence of prophylactic vaccination, “PrEP” remains a promising approach to control the spread of transmission and slow the HIV epidemic.”

This has probably been pointed out, from the Cytodyn link you posted. Interesting it’s mentioned re: long-acting LL. Live Immune makes sense in that context.